3SBio (沈阳三生制药) and Ascentage Pharma will develop targeted cancer therapeutics focusing on programmed cell death; Allele Biotech was granted a China patent with far-reaching claims for RNAi; Private equity investors in the west currently find emerging markets, especially China, an attractive investment; Gorbec Pharm will open a GMP-compliant analytical laboratory in Yantai; NeoStem priced a public offering of 5,000,000 shares; 3SBio in-licensed the China rights to a phosphate binder for dialysis patients; Simcere Pharma (先声药业) received SFDA approval to market  the flu drug Relenza; Celsis In Vitro Technologies found a China distributor for its drug discovery products; OrbusNeich began a China clinical trial of its Genous Bio-engineered R stent; and Tianyin Pharma reported positive results for its fiscal Q2. More details...

Stock Symbols: (NSDQ: SSRX) (NYSE Amex: NBS) (NYSE: SCR) (NYSE Alternext: TPI)